Not investment advice. FilingSight is an automated analytical research tool, not a registered investment advisor. Ratings and scores are quantitative analytical classifications, not buy or sell recommendations. Nothing here is personalized to your circumstances. Investing involves risk of loss — consult a licensed professional. See full disclosures.
HCA Healthcare
HCAHealthcareGenerated Aug 19, 2026, 06:24 PM UTC
HCA (HCA Healthcare) analytical snapshot. Revenue grew +7.1% YoY to $75.60B. Net margin at 8.97% (contracting ▼). Return on equity -112.56%, ROA 11.17%, ROIC 0.00%. Market cap $91.42B at $412.09 per share. Trailing P/E 14.55, P/S 1.21. FCF DCF intrinsic value ≈ $564.46 → implied upside +37.0%. Risk: Elevated. Macro: Risk-on · Supportive. Composite analytical score 9 (data confidence 82%). Descriptive analytics from public filings — not investment advice.
Free SEC analysis
— computed from SEC filings, free to readFilings & Ownership
Latest annual report (10-K) filed Feb 10, 2026. Latest quarterly report (10-Q) filed Jul 28, 2026. 22 recent 8-K material-event filings in the index.
- Latest annual report (10-K) filed Feb 10, 2026.
- Latest quarterly report (10-Q) filed Jul 28, 2026.
- 22 recent 8-K material-event filings in the index.
- Recent insider Form 4s: 0 buy vs 0 sell transactions.
- ~10,000+ recent 13F-HR filings reference HCA Healthcare; broad institutional reporting.
- Recent filers include DSC Advisors, L.P., HOMANS PETER, BRANT POINT INVESTMENT MANAGEMENT LLC.
- 20 recent 13G passive institutional ownership notices.
| Filer | Form | Filed |
|---|---|---|
| DSC Advisors, L.P. | 13F-HR | May 15, 2020 |
| HOMANS PETER | 13F-HR | Jan 15, 2003 |
| BRANT POINT INVESTMENT MANAGEMENT LLC | 13F-HR | Feb 13, 2025 |
| Delta Accumulation, LLC | 13F-HR | May 8, 2026 |
| DSC Advisors, L.P. | 13F-HR | Nov 14, 2017 |
| Date | Form | Description |
|---|---|---|
| Jul 29, 2026 | 8-K | 8-K |
| Jul 24, 2026 | 8-K | 8-K |
| Jul 14, 2026 | 8-K | 8-K |
| Jun 18, 2026 | 8-K | 8-K |
| Apr 30, 2026 | 8-K | 8-K |
| Apr 28, 2026 | 8-K | 8-K |
| Apr 27, 2026 | 8-K | 8-K |
| Apr 24, 2026 | 8-K | 8-K |
SEC Filing Deep-Analysis
1 risk signal(s), 1 positive signal(s), 2 watch item(s) detected from XBRL filing diff analysis. 1 positive signal(s) versus 1 risk signal(s). The filing exhibits more constructive indicators than concerns, though individual risk factors should still be monitored.
- NEW: Restatement of financial statements in latest filing: The term "restatement of" "previously issued" appears in recent 10-K/10-Q filings but was NOT present in the prior 24-month period. This is a new risk disclosure that warrants attention. Found in 1 filing(s).
- Operating cash flow exceeds net income: OCF is 1.86x net income, indicating high earnings quality — cash conversion is strong and accruals are not inflating reported profits.
- NEW: Impairment charge: Impairment charge appears in recent filings but not in the prior 24-month period. Monitor for materiality.
- NEW: Off-balance sheet arrangements: Off-balance sheet arrangements appears in recent filings but not in the prior 24-month period. Monitor for materiality.
- Endogenous analysis: 1 positive signal(s) versus 1 risk signal(s). The filing exhibits more constructive indicators than concerns, though individual risk factors should still be monitored.
- 20 disclosure(s) dropped from prior year — reduced reporting granularity.
- 3 new risk-language term(s) detected in filing text: Restatement of financial statements, Impairment charge, Off-balance sheet arrangements.
| Metric | Prior year | Latest year | Change | % Change |
|---|---|---|---|---|
| Revenue | $70.60B | $75.60B | $5.00B | +7.1% |
| Net income | $5.76B | $6.78B | $1.02B | +17.8% |
| Operating cash flow | $10.51B | $12.64B | $2.12B | +20.2% |
| Capex | $4.88B | $4.94B | $69.0M | +1.4% |
| Total assets | $59.51B | $60.72B | $1.21B | +2.0% |
| Total liabilities | $42.13B | $45.62B | $3.50B | +8.3% |
| Long-term debt | $43.03B | $44.28B | $1.25B | +2.9% |
| Cash & equivalents | $1.93B | $1.04B | $-893.0M | -46.2% |
| Stockholders equity | $-2.50B | $-6.03B | $-3.53B | -141.2% |
| Inventory | $1.74B | $1.65B | $-86.0M | -4.9% |
| Accounts receivable | $10.75B | $10.87B | $116.0M | +1.1% |
| Interest expense | $2.06B | $2.25B | $187.0M | +9.1% |
| Type | Concepts |
|---|---|
| Removed | AccrualForTaxesOtherThanIncomeTaxesCurrent, AccruedEmployeeBenefitsCurrent, AmortizationOfFinancingCosts, AmortizationOfIntangibleAssets, BuildingsAndImprovementsGross, ConstructionInProgressGross, CurrentFederalTaxExpenseBenefit, CurrentForeignTaxExpenseBenefit, CurrentStateAndLocalTaxExpenseBenefit, DeferredFederalIncomeTaxExpenseBenefit |
| Term | Severity | Recent | Prior | Status |
|---|---|---|---|---|
| Restatement of financial statements | high | 1 | 0 | NEW |
| Impairment charge | medium | 5 | 0 | NEW |
| Restructuring | medium | 5 | 8 | Ongoing |
| Off-balance sheet arrangements | medium | 5 | 0 | NEW |
| Related party transactions | low | 5 | 2 | Ongoing |
Fundamentals
Revenue grew +7.1% YoY to $75.60B. Net margin at 8.97% (contracting ▼). Return on equity -112.56%, ROA 11.17%, ROIC 0.00%.
- Revenue grew +7.1% YoY to $75.60B.
- Net margin at 8.97% (contracting ▼).
- Return on equity -112.56%, ROA 11.17%, ROIC 0.00%.
- Gross margin 0.00%, operating margin 0.00%.
- Free cash flow margin 10.17% ($7.69B).
- Net income up ▲ +17.8% YoY.
- Debt/equity -7.04, current ratio 0.83, net debt $43.43B.
- Asset turnover 1.23 — capital efficiency.
| FY | Revenue | Rev YoY | Gross% | Op% | Net% | FCF | ROE% |
|---|---|---|---|---|---|---|---|
| 2024 | $70.60B | +8.7% | 0.00 | 0.00 | 8.16 | $5.64B | -230.49 |
| 2025 | $75.60B | +7.1% | 0.00 | 0.00 | 8.97 | $7.69B | -112.56 |
| Quarter end | Revenue | YoY | QoQ | Net margin |
|---|---|---|---|---|
| Jun 30, 2024 | $17.49B | +10.3% | — | 8.35% |
| Sep 30, 2024 | $17.49B | +7.9% | -0.0% | 7.26% |
| Mar 31, 2025 | $18.32B | +5.7% | +4.8% | 8.79% |
| Jun 30, 2025 | $18.61B | +6.4% | +1.6% | 8.88% |
| Sep 30, 2025 | $19.16B | +9.6% | +3.0% | 8.57% |
| Mar 31, 2026 | $19.11B | +4.3% | -0.3% | 8.48% |
Pro analysis — preview
— score, signals & key metrics shown; full reasoning lockedValuation
Market cap $91.42B at $412.09 per share. Trailing P/E 14.55, P/S 1.21. FCF DCF intrinsic value ≈ $564.46 → implied upside +37.0%.
- Market cap $91.42B at $412.09 per share.
Price & Technicals
Price $412.09 — downtrend (below 200-DMA); 1-month momentum positive. RSI(14) 52.92.
- Price $412.09 — downtrend (below 200-DMA); 1-month momentum positive.
Macro & Rates
Risk-on · Supportive. Real GDP growth 1.50% (quarterly, as of Apr 1, 2026). CPI inflation +3.3% YoY. Fed funds rate 3.63%, 10Y Treasury 4.72%.
- Market regime: Risk-on · Supportive.
Risk Scorecard
Composite risk Elevated. Leverage debt/equity -7.04 (low). Liquidity current ratio 0.83 (stretched).
- Composite risk: Elevated.
See the full picture behind every stock
Unlock the complete 10-year fundamentals, DCF & Graham intrinsic value, 13F/13D ownership flow, risk scorecard, multi-analyst bull/bear debate — plus watchlist alerts and your research workspace. Start with a 14-day Pro trial.
3 sections free · 4 Pro previews · composite 9
Macro exposure
Defensive · Low sensitivityMacro regime: Risk-on · Supportive. HCA Healthcare is a defensive name (low macro sensitivity) — a supportive backdrop, though defensives lag risk-on tapes.
Analytical read
deterministic previewMarket cap $91.42B at $412.09 per share..
Peer comparison
Defensive groupHow HCA stacks up against tracked peers with similar macro sensitivity — by analytical score and macro exposure.
| Company | Score | Macro |
|---|---|---|
| DexCom Inc. DXCM | 19 | Neutral |
| Bristol-Myers Squibb BMY | 19 | Neutral |
| Eli Lilly & Co. LLY | 17 | Neutral |
| HCA Healthcare HCA● you | 9 | Neutral |
| Gilead Sciences GILD | 8 | Neutral |
| Johnson & Johnson JNJ | 8 | Neutral |
| Abbott Laboratories ABT | 7 | Neutral |
| Biogen Inc. BIIB | 7 | Neutral |
| Intuitive Surgical Inc. ISRG | 7 | Neutral |
| Coca-Cola Co. KO | 6 | Neutral |
| Zoetis Inc. ZTS | 6 | Neutral |
| Thermo Fisher Scientific TMO | 3 | Neutral |
| Regeneron Pharmaceuticals REGN | 3 | Neutral |
| Danaher Corp. DHR | 1 | Neutral |
| Merck & Co. MRK | 0 | Neutral |
| Illumina Inc. ILMN | 0 | Neutral |
| Colgate-Palmolive CL | -2 | Neutral |
| Vertex Pharmaceuticals VRTX | -2 | Neutral |
| AbbVie Inc. ABBV | -7 | Neutral |
| Procter & Gamble PG | -7 | Neutral |
| CVS Health Corp. CVS | -8 | Neutral |
| Walmart Inc. WMT | -8 | Neutral |
| Mondelez International MDLZ | -10 | Neutral |
| Amgen Inc. AMGN | -10 | Neutral |
| Cigna Group CI | -11 | Neutral |
| Kroger Co. KR | -12 | Neutral |
| Costco Wholesale COST | -14 | Neutral |
| Pfizer Inc. PFE | -15 | Neutral |
| PepsiCo Inc. PEP | -16 | Neutral |
| Sysco Corp. SYY | -16 | Neutral |
| Hershey Co. HSY | -17 | Neutral |
| Kimberly-Clark Corp. KMB | -18 | Neutral |
| Moderna Inc. MRNA | -21 | Neutral |
| UnitedHealth Group UNH | -25 | Neutral |